著者

長井 紀章

出版者

日本白内障学会

雑誌

日本白内障学会誌 (ISSN:09154302)

巻号頁・発行日

vol.31, no.1, pp.17-19, 2019 (Released:2019-07-30)

参考文献数

6

著者

武田 峻 山本 直樹 長井 紀章 出口 粧央里 平松 範子 初坂 奈津子 永田 万由美 松島 博之 久保 江理 佐々木 洋

出版者

日本白内障学会

雑誌

日本白内障学会誌 (ISSN:09154302)

巻号頁・発行日

vol.34, no.1, pp.76-82, 2022 (Released:2022-07-19)

参考文献数

32

---

核白内障(nuclear cataract: NUC)の発症要因として,高温環境による影響が報告されている.今回,体温に着目し,水晶体再建術施行例を対象とし,体温とヒト水晶体上皮細胞(human lens epithelial cells: HLECs)中ミトコンドリア活性およびATP含量の関係,体温とNUC発症リスクの関連について検討した.NUC患者では体温36.5℃以下患者(L群)に比べ36.5℃超過の患者(H群)でHLECs中のミトコンドリアゲノムチトクロムcオキシダーゼmRNA発現量は増加傾向を示した.また,H群におけるATP量はNUC患者が透明水晶体患者に比較し高く,NUC患者ではL群より有意に高値を示した.一方,ロジスティック回帰分析によるL群に対するH群のNUC発症リスクのオッズ比は1.131(95% 信頼区間: 0.583-2.193)であり,有意な関連性は認められなかった.

著者

稲葉 一訓 本多 公貴 大竹 裕子 岡本 紀夫 下村 嘉一 小竹 武 長井 紀章

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.46, no.2, pp.93-99, 2020-02-10 (Released:2021-02-10)

参考文献数

6

---

We proposed an in vitro test based on pH changes in ophthalmic solutions with the addition of lacrimal buffer, and examined anti-allergic ophthalmic solutions (acitazanolast hydrate, amlexanox, epinastine hydrochloride, ketotifen fumarate, levocabastine hydrochloride, olopatadine hydrochloride, pemirolast potassium, sodium cromoglycate, and tranilast) and anti-glaucoma ophthalmic solutions (brimonidine tartrate, carteolol hydrochloride, dorzolamide hydrochloride, isopropyl unoprostone, pilocarpine hydrochloride, timolol maleate, and travoprost) by using the in vitro test. Resistance to the lacrimal buffer capacity of ketotifen ophthalmic solution was higher than that of the other anti-allergic ophthalmic solutions tested. Among anti-glaucoma ophthalmic solutions, resistance to the lacrimal buffer capacity of the isopropyl unoprostone and dorzolamide ophthalmic solutions was higher than that of the other ophthalmic solutions tested. We also found relationships between ophthalmic additives and the pH-buffering effect in ophthalmic solutions, and demonstrated that D-mannitol, which is an ophthalmic additive, resisted the pH-buffering effect in artificial tears. Furthermore, high resistance was observed to the lacrimal buffer capacities of ophthalmic solutions with D-mannitol. These results will contribute to further studies aimed at reducing irritation caused by ophthalmic solutions.

著者

長井 紀章

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.141, no.1, pp.47-53, 2021-01-01 (Released:2021-01-01)

参考文献数

19

被引用文献数

1 3

---

The use of eye drops is a well-established practice in the treatment of ophthalmic diseases, although the bioavailability of traditional eye drops, which are either solutions or suspensions, is insufficient, as the corneal barrier and dilution by lacrimation prevent the transcorneal penetration of drugs. Additionally, frequent instillation may cause undesirable systemic side effects and local corneal toxicity. To overcome these problems, micro- and nanoparticles, hydrogels, and viscous solutions have been tested, and solid nanoparticles are also expected to be applied. This review examines the usefulness of ophthalmic formulations based on solid nanoparticles, by using the specific example of indomethacin (IMC). Ophthalmic formulations based on solid IMC nanoparticles (IMC-NP dispersions) have been prepared using various additives (benzalkonium chloride, mannitol, methylcellulose, and cyclodextrin) and a rotation/revolution pulverizer (NP-100), to produce particles of 50-220 nm in size. The solubility of IMC in IMC-NP dispersions was 4.18-fold higher than that in the suspensions containing IMC microparticles (IMC-MP suspensions), and IMC-NP dispersions were better tolerated than commercially available NSAIDs eye drops, such as IMC, pranoprofen, diclofenac, bromfenac, and nepafenac eyedrops, in human corneal epithelial cells. Moreover, the corneal penetration in IMC-NP dispersions was higher than that in commercially available IMC and IMC-MP suspensions, and three energy-dependent endocytosis pathways (clathrin-dependent endocytosis, caveolae-dependent endocytosis, and macropinocytosis) were related to the high ophthalmic bioavailability of IMC-NP dispersions. This information can be used to support future studies aimed at designing novel ophthalmic formulations.

著者

小畑 友紀雄 出口 粧央里 山口 瑞季 稲葉 一訓 長井 紀章 中田 雄一郎

雑誌

日本薬学会第142年会(名古屋)

巻号頁・発行日

2022-02-01

著者

小竹 武 松本 優里香 塚本 あゆみ 井上 知美 石渡 俊二 草薙 みか 坂野 千賀 大里 恭章 伊藤 吉將 長井 紀章

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.41, no.11, pp.786-792, 2015-11-10 (Released:2016-11-10)

参考文献数

6

---

We investigated whether the component in cataplasm transmitted into hemorrhoid ointment in the combined storage of hemorrhoid ointment and non-steroidal anti-inflammatory drugs (NSAIDs) cataplasm. The NSAIDs cataplasm was used as a commercially available methyl salicylate (MS reishippu “TAIHO”, MS cataplasm) and indomethacin (Catlep®, IMC cataplasm) cataplasm. In addition, the hemorrhoid ointment was in a polyethylene container with (Neriproct® ointment, DFV-L ointment) or without aluminum laminate (Posterisan® forte, HC ointment). As for the methyl salicylate, 5.68 mg / pieces in HC ointment were detected at 40 weeks of combined storage with MS cataplasm. The methyl salicylate concentration in DFV-L ointment was lower than that in HC ointment under the same conditions. On the other hand, no contamination of indomethacin in HC and DFV-L ointment was observed in the combined storage with IMC cataplasm. These results show that the methyl salicylate in cataplasm passed the polyethylene container, and provide significant information on the risk of contamination by the combined storage of cataplasm and hemorrhoid ointment.

著者

長井 紀章

出版者

日本白内障学会

雑誌

日本白内障学会誌 (ISSN:09154302)

巻号頁・発行日

vol.30, no.1, pp.65-67, 2018 (Released:2018-07-05)

参考文献数

6

著者

長井 紀章

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.136, no.10, pp.1385-1390, 2016 (Released:2016-10-01)

参考文献数

20

被引用文献数

5

---

The ophthalmic application of drugs is the primary route of administration for the therapy of glaucoma; however, in traditional formulations, only small amounts of the administered drug penetrate the cornea to reach the desired intraocular tissue due to corneal barriers. Recently, nanoparticulate drug delivery is expected as a technology to overcome the difficulties in delivering drugs across biological barriers (improvement of bioavailability). In this study, we attempted to establish a new method for preparing solid drug nanoparticles by using a bead mill and various additives, and succeeded in preparing a high quality dispersion containing drug nanoparticles. For a more concrete example, a mean particle size of disulfiram (DSF) treated with bead mill is 183 nm. The corneal penetration and corneal residence time of DSF from the ophthalmic dispersion containing DSF nanoparticles were significantly higher than those from a 2-hydroxypropyl-β-cyclodextrin solution containing DSF (DSF solution). It is known that the administration of DSF has intraocular pressure (IOP)-reducing effects. The IOP-reducing effects of the ophthalmic dispersion containing DSF nanoparticles were significantly greater than those of the DSF solution in rabbits (the IOP was enhanced by placing the rabbits in a dark room for 5 h). In addition, the ophthalmic dispersion containing DSF nanoparticles is better tolerated by corneal epithelial cells than DSF solution. It is possible that dispersions containing DSF nanoparticles provide new possibilities for effectively treating glaucoma, and that ocular drug delivery systems using drug nanoparticles may expand their usage for therapy in the ophthalmologic field.